|Bid||95.90 x 800|
|Ask||99.97 x 2200|
|Day's Range||91.65 - 96.50|
|52 Week Range||70.73 - 96.50|
|Beta (5Y Monthly)||0.33|
|PE Ratio (TTM)||330.41|
|Earnings Date||Oct 25, 2022 - Oct 31, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||111.95|
Subscribe to Yahoo Finance Plus to view Fair Value for BMRN
BioMarin Pharmaceutical Inc's (NASDAQ: BMRN) Q2 sales reached $533.8 million, up 6% Y/Y, beating the consensus of $521.47 million. BioMarin said the increase was achieved "despite continued erosion of the U.S. Kuvan market." Total revenues grew 13% Y/Y, excluding Kuvan. The company reported EPS of $0.15 compared to $0.07 a year ago, beating the consensus of $0.11. Voxzogo for achondroplasia (dwarfism) reported sales of $34.4 million. An estimated 446 children were being treated with commercial V
Biomarin Pharmaceutical's (BMRN) second-quarter earnings and sales beat estimates. BMRN slightly raises its sales guidance for the year.
BioMarin (BMRN) delivered earnings and revenue surprises of 37.21% and 3.82%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?